Aflibercept monotherapy or “bevacizumab first” for diabetic macular edema assessed the evidence on visual outcomes and costs to the healthcare system.
Researchers in the Diabetic Retinopathy Clinical Research (DRCR) Retina Network has reported that the treatment of moderate vision loss due to diabetic macular edema found… Read More »Aflibercept monotherapy or “bevacizumab first” for diabetic macular edema assessed the evidence on visual outcomes and costs to the healthcare system.